Voyageur Pharmaceuticals Ltd. (TSXV: VM)
Health Care · Pharmaceuticals · CA
CA$0.16
-3.13% today · -8.8% 1Y
Voyageur Pharmaceuticals Ltd. (TSXV: VM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $25.48M and employs 49 people.
Over the last twelve months the share price has lost 8.8%, trading between 0.07 and 0.20.
Tweenvest scores Voyageur Pharmaceuticals Ltd. across four factors: quality 19/100, value 69/100. Its strongest factor is value.
VM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.48M
- Revenue (TTM)
- $34.27K
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.29
- 52-week high
- CA$0.20
- 52-week low
- CA$0.07
- Avg volume (3M)
- —
- Shares outstanding
- 226.34M
- Employees
- 49
- Next earnings
- —
About Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.
- ISIN
- CA92918C1014
- Listed since
- Jul 24, 2013
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.